Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

Core Viewpoint - The announcement highlights the commencement of filming for the urban medical emotional drama "Asking the Heart 2," produced by Lingmeng Film and Television, Tencent Video, and iQIYI, indicating a strategic collaboration among major players in the media industry [1] Group 1: Production Details - "Asking the Heart 2" began filming on September 27, 2025 [1] - The series is written by Zhou Yifei and directed by Li Zhi, with Xu Xiaowu serving as the executive producer [1] - Notable cast members include Zhao Youting and Mao Xiaotong in leading roles, with Jin Shijia in a special role and Zhang Jianing as a guest lead [1]

Core Viewpoint - The announcement highlights the commencement of filming for the urban medical emotional drama "Ask the Heart 2," produced by Lingmeng Film and Television, Tencent Video, and iQIYI, indicating a strategic collaboration among major players in the entertainment industry [1] Group 1 - The filming of "Ask the Heart 2" began on September 27, 2025 [1] - The series is written by Zhou Yifei and directed by Li Zhi, showcasing a strong creative team [1] - Xu Xiaowu serves as the executive producer, with Wang Ye and Chen Shuze as producers, indicating a well-structured production team [1] Group 2 - The lead roles are played by Zhao Youting and Mao Xiaotong, with Jin Shijia in a special role and Zhang Jianing as a guest lead, suggesting a star-studded cast that may attract viewership [1]

自願公告 業務發展最新情況 本公告乃經檸萌影視傳媒有限公司（「本公司」或「檸萌影視」，連同其附屬公司及併表聯屬 實體統稱「本集團」）自願作出，旨在向本公司股東及潛在投資者更新本集團之最新業務發 展。 本公司董事會（「董事會」）欣然宣佈，由檸萌影視、騰訊視頻、愛奇藝出品的都市醫療情 感話題劇《問心2》，已於2025年9月27日開機拍攝，該劇由周藝飛編劇，黎志執導，徐曉 鷗擔任總製片人，王也、陳抒澤任製片人，趙又廷、毛曉彤領銜主演，金世佳特別主 演，張佳寧特邀領銜。 Linmon Media Limited 9857 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 董事長 蘇曉 中國，北京 2025年9月28日 於本公告日期，本公司執行董事為蘇曉先生、陳菲女士及徐曉鷗女士；本公司非執行董 事為王娟女士及張嶸先生；本公司獨立非執行董事為蔣昌建先生、唐松蓮女士及梁寧女 士。 承董事會命 檸萌影視傳媒有限公司 ...